Argenx Se (ARGX) Cash & Equivalents (2015 - 2026)
Argenx Se's (ARGX) quarterly Cash & Equivalents came in at $3.6 billion in Q2 2026, up 71.81% on a YoY basis from $2.1 billion in Q2 2025, and up 2.66% quarter-over-quarter from $3.5 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Cash & Equivalents (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Cash & Equivalents for 12 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Equivalents rose 71.81% year-over-year to $3.6 billion; the trailing twelve-month figure through Jun 2026 stood at $3.6 billion (up 71.81% YoY), and the FY2025 full-year result was $3.5 billion, up 132.73% from the prior year.
- Cash & Equivalents grew to $3.6 billion in Q2 2026 per ARGX's latest filing, from $3.5 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $3.6 billion in Q2 2026 and bottomed at $800.7 million in Q4 2022.
- Historically, Cash & Equivalents has averaged $1.9 billion across 5 years, with a median of $1.5 billion in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 40.0% in 2022, then surged 155.87% in 2023.
- Over 5 years, Cash & Equivalents stood at $800.7 million in 2022, then soared by 155.87% to $2.0 billion in 2023, then fell by 26.79% to $1.5 billion in 2024, then surged by 132.73% to $3.5 billion in 2025, then grew by 2.66% to $3.6 billion in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $3.6 billion, $3.5 billion, and $2.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 6.14 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 2.46 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 3.58 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 1.72 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 544.80 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 11.32 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.49 Bn |
| Jun 30, 2025 | 2.09 Bn |
| Dec 31, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Dec 31, 2023 | 2.05 Bn |
| Jun 30, 2023 | 1.11 Bn |
| Dec 31, 2022 | 800.74 Mn |
| Jun 30, 2022 | 1.37 Bn |
| Dec 31, 2021 | 1.33 Bn |
| Jun 30, 2021 | 1.58 Bn |
| Dec 31, 2020 | 1.18 Bn |
| Jun 30, 2020 | 1.35 Bn |
| Dec 31, 2019 | 366.69 Mn |
| Jun 30, 2019 | 188.54 Mn |
| Dec 31, 2018 | 320.78 Mn |
| Jun 30, 2018 | 168.12 Mn |
| Dec 31, 2017 | 224.73 Mn |
| Jun 30, 2017 | 83.05 Mn |
| Dec 31, 2016 | 97.06 Mn |